title: Nivolumab plus ipilimumab in the treatment of advanced melanoma.
abstract: Advanced melanoma has historically been a difficult disease to treat due to few effective systemic treatment options. However, over the past few years, scientific advancements in immune checkpoint inhibition have resulted in several novel approaches that have changed front-line management of advanced melanoma. Despite these exciting developments, there remains room for improvement in treatment outcomes. Combination immunotherapy, in particular combined cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death 1 (PD-1) blockade, represents an important first step in this direction.
authors.affiliation: Helen Diller Comprehensive Cancer Center, University of California, 1600 Divisadero St., Box 1770, San Francisco, CA, 94115, USA. Katy.Tsai@ucsf.edu.
authors.forename: Katy K
authors.initials: KK
authors.lastname: Tsai
authors.affiliation: Helen Diller Comprehensive Cancer Center, University of California, 1600 Divisadero St., Box 1770, San Francisco, CA, 94115, USA. Adil.Daud@ucsf.edu.
authors.forename: Adil I
authors.initials: AI
authors.lastname: Daud
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D015337:Multicenter Studies as Topic / Q000523:psychology; D000077594:Nivolumab; D016032:Randomized Controlled Trials as Topic; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000074324:Ipilimumab; D000077594:Nivolumab